Aclarion Adds First Private Practice Site to CLARITY Trial, Boosting Enrollment Efforts
ACON sits 36% above its 52-week low of $2.34 on light trading volume (0.3× avg).
Summary
Aclarion, Inc. announced the addition of Lanman Spinal Neurosurgery, its first private practice site in Los Angeles, to the CLARITY trial for its Nociscan solution. This strategic expansion aims to accelerate patient enrollment in the pivotal study, which evaluates Nociscan's ability to improve surgical outcomes for chronic low back pain. For a micro-cap healthcare technology company, expanding clinical trial sites, particularly into the private practice setting, is a material positive development as it indicates broader interest and potential for real-world integration of its technology. This progress is crucial for generating the high-quality evidence needed for Nociscan's commercialization and brings the company closer to its anticipated Q4 2026 interim data readout. Investors will be watching for continued enrollment updates and the upcoming data disclosure.
At the time of this announcement, ACON was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $2.34 to $12.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.